{"id":531544,"date":"2021-02-24T07:42:01","date_gmt":"2021-02-24T07:42:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=531544"},"modified":"2021-02-24T07:42:01","modified_gmt":"2021-02-24T07:42:01","slug":"atrial-fibrillation-market-size-share-epidemiology-and-competitive-analysis-2030-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/atrial-fibrillation-market-size-share-epidemiology-and-competitive-analysis-2030-by-delveinsight_531544.html","title":{"rendered":"Atrial Fibrillation Market Size, Share, Epidemiology and Competitive Analysis 2030 by DelveInsight"},"content":{"rendered":"
\"Atrial<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Atrial Fibrillation – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Atrial Fibrillation, historical and forecasted epidemiology as well as the Atrial Fibrillation market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight launched a new report on Atrial Fibrillation Market Insights, Epidemiology, and Market Forecast-2030<\/a>.<\/strong><\/p>\n

DelveInsight’s “Atrial Fibrillation Market Report 2030<\/strong><\/a>” delivers an in-depth understanding of the Atrial Fibrillation, historical and forecasted epidemiology as well as the Atrial Fibrillation market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.<\/p>\n

\"\"<\/p>\n

Atrial Fibrillation (AF) is the most common sustained cardiac arrhythmia. AF is often associated with other chronic cardiovascular conditions, including hypertension and heart failure, and long-term AF can result in a significantly raised risk of stroke – an estimated 15% of all strokes are caused by AF, and it accounts for one-third of strokes in individuals aged 65 years or older.<\/p>\n

Owing to the complexity of Atrial Fibrillation (AF), and the broad range of symptoms and comorbidities AF patients present, a number of pharmacological strategies are used to treat AF. The current medical practice focuses on the use of drugs to either establish normal sinus rhythm or to control heart rates in AF patients. The treatment mainly depends on the class of AF, the age of the patient, the presence of several comorbidities, such as heart disease, and the estimated risk of stroke.<\/p>\n

A wide range of treatments is available for the management of AF, including pharmacological therapy, surgical procedures,<\/strong> and medical devices<\/strong>. Pharmacological treatment for AF consists of two elements: treatment for control of the ventricular rate or rhythm, and antithrombotic agents to prevent stroke. <\/p>\n

Request for a detailed sample report: https:\/\/www.delveinsight.com\/sample-request\/atrial-fibrillation-market<\/span><\/a><\/strong><\/p>\n

Atrial Fibrillation key pharma players involved:<\/strong><\/p>\n

1 Bristol-Myers Squibb<\/strong><\/p>\n

2. ARCA Biopharma<\/strong><\/p>\n

3. Omeicos Therapeutics GmbH<\/strong><\/p>\n

Click here and get access to a free sample page.<\/strong><\/a><\/p>\n

Table of contents<\/strong><\/p>\n

1 Key Insight
2 Executive Summary of Atrial Fibrillation
3 Atrial Fibrillation Market Overview at a Glance
4 Disease Background and Overview: Atrial Fibrillation
5 Case Reports
6 Atrial Fibrillation Epidemiology and Patient Population
7 United States Epidemiology
8 EU5 Epidemiology
9 Japan Epidemiology
10 Current Atrial Fibrillation Treatment and Medical Practices
11 Unmet needs
12 Atrial Fibrillation Marketed Drugs
13 Atrial Fibrillation Emerging Drugs
14 Atrial Fibrillation 7MM Market Analysis
15 United States
16 EU-5 countries: Market Outlook
17 Japan Market Outlook
18 Atrial Fibrillation Market Drivers
19 Atrial Fibrillation Market Barriers
20 SWOT Analysis
21 Reimbursement and market access
22 Appendix
23 DelveInsight Capabilities
24 Disclaimer
25 About DelveInsight<\/p>\n

Download report: https:\/\/www.delveinsight.com\/report-store\/atrial-fibrillation-market<\/a><\/strong><\/p>\n

About DelveInsight<\/strong>
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/strong><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP DelveInsight’s “Atrial Fibrillation – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Atrial Fibrillation, historical and forecasted epidemiology as well as the Atrial Fibrillation market trends in the United States, EU5 … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-531544","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/531544","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=531544"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/531544\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=531544"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=531544"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=531544"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}